Sattui Sebastian E, Jannat-Khah Deanna, Lally Lindsay, Lieber Sarah B, Mandl Lisa A, Spiera Robert F
Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY.
Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Rheumatology (Oxford). 2022 Nov 2;61(11):4455-4464. doi: 10.1093/rheumatology/keac050.
To describe the prevalence of frailty in a single-centre cohort of patients with PMR and describe its association with health-related quality of life (HRQoL), cognition and sarcopenia.
This was a cross-sectional study of patients with PMR, according to 2012 EULAR/ACR Classification Criteria, presenting within 12 months of diagnosis and on treatment with glucocorticoids. Frailty was defined according to the Fried frailty criteria. HRQoL was assessed using Patient-Reported Outcomes Measurement Information System Computerized Adaptive Test (PROMIS-CAT) and cognition was assessed using the Mini-Mental State Examination. Sarcopenia was measured by DXA.
Forty-one patients were enrolled. Prevalence of frailty and pre-frailty was 17% and 59%, respectively. Frail patients had higher inflammatory markers at diagnosis compared with pre-frail and robust patients. Of 27 patients with DXA results, 26% were sarcopenic. Frail patients had worse physical function, and more pain behaviour and interference compared with pre-frail and robust patients. In univariable analyses, frail patients were more likely to have worse physical function, and more pain behaviour and pain interference, which remained significant after adjusting for age. There were no significant associations between cognition or sarcopenia and frailty.
In this cohort of PMR patients, there was a higher prevalence of frailty and pre-frailty compared with that reported in community-dwelling elderly. Frailty was associated with worse physical function, and increased pain behaviour and pain interference, differences that were also clinically meaningful. Larger prospective studies are needed to confirm these findings and analyse the association of frailty with other PMR disease outcomes.
描述单中心队列中巨细胞动脉炎(PMR)患者的衰弱患病率,并描述其与健康相关生活质量(HRQoL)、认知及肌肉减少症的关联。
这是一项针对PMR患者的横断面研究,依据2012年欧洲抗风湿病联盟(EULAR)/美国风湿病学会(ACR)分类标准,纳入诊断后12个月内且正在接受糖皮质激素治疗的患者。根据弗里德衰弱标准定义衰弱。使用患者报告结局测量信息系统计算机自适应测试(PROMIS-CAT)评估HRQoL,使用简易精神状态检查表评估认知。通过双能X线吸收法(DXA)测量肌肉减少症。
共纳入41例患者。衰弱和衰弱前期的患病率分别为17%和59%。与衰弱前期和非衰弱患者相比,衰弱患者诊断时的炎症标志物水平更高。在27例有DXA结果的患者中,26%存在肌肉减少症。与衰弱前期和非衰弱患者相比,衰弱患者的身体功能更差,疼痛行为及疼痛干扰更多。在单变量分析中,衰弱患者更有可能身体功能更差,疼痛行为及疼痛干扰更多,在调整年龄后这些差异仍具有统计学意义。认知或肌肉减少症与衰弱之间无显著关联。
在这个PMR患者队列中,与社区居住老年人报告的情况相比,衰弱和衰弱前期的患病率更高。衰弱与更差的身体功能、更多的疼痛行为及疼痛干扰相关,这些差异在临床上也具有意义。需要更大规模的前瞻性研究来证实这些发现,并分析衰弱与其他PMR疾病结局的关联。